Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biopharmaceutical company focused on medicines for genetic diseases, and its news flow reflects both commercial activity and clinical development progress. Company updates frequently highlight Attruby (acoramidis), a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Investors following BBIO news see regular disclosures on Attruby’s commercial performance and new clinical and real-world data from the ATTRibute-CM program and its open-label extension, including analyses of variant ATTR-CM populations and specific genetic subgroups. BridgeBio also reports on late-stage pipeline milestones, such as Phase 3 results for BBP-418 in LGMD2I/R9, topline data and regulatory plans for encaleret in autosomal dominant hypocalcemia type 1, and registrational studies of infigratinib in children with skeletal dysplasias.
News items often include participation in major medical and investor conferences, where BridgeBio presents moderated digital posters, scientific analyses, and corporate updates. Additional releases cover financial and corporate developments, including quarterly business updates, equity inducement grants, royalty monetization transactions related to acoramidis, and proposed offerings of convertible senior notes.
This BBIO news page on Stock Titan aggregates these announcements so readers can review clinical data disclosures, commercial updates, financing transactions, and governance developments in one place. For investors and observers tracking genetic disease drug development and ATTR-CM therapies, the news feed provides a concise view of BridgeBio’s reported progress and key events over time.
BridgeBio Pharma (Nasdaq: BBIO) announced an upcoming investor webinar scheduled for September 10, 2025, at 8:00 am ET. The webinar will feature Dr. Rachel Gafni, Senior Research Physician at the National Institute of Dental and Craniofacial Research (NIH) and Principal Investigator for the CALIBRATE Phase 3 trial.
The presentation will focus on autosomal dominant hypocalcemia type 1 (ADH1), including disease pathophysiology, unmet medical needs, and the potential of encaleret as a treatment. Executive team members will discuss the ongoing Phase 3 CALIBRATE study, with topline results expected in fall 2025.
BridgeBio Pharma (Nasdaq: BBIO) announced upcoming presentations at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025 in Seattle. The company will present Phase 2 data for encaleret in post-surgical hypoparathyroidism through an oral presentation by Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research.
Additionally, two poster sessions focusing on skeletal dysplasia research will be presented by Dr. Bhavik Shah, showcasing data on infigratinib's effects on bone growth in hypochondroplasia and skull measures in Crouzon/Pfeiffer Syndromes mouse models.
BridgeBio Pharma (Nasdaq: BBIO) announced significant results from the ATTRibute-CM open label extension study of acoramidis through Month 42. The drug demonstrated a 44% reduction in cardiovascular mortality risk for patients with ATTR-CM. Additional key findings include a 46% hazard reduction in the composite outcome of cardiovascular mortality or first cardiovascular hospitalization.
The study showed that acoramidis, marketed as Attruby® in the US and BEYONTTRA® in Europe, achieved disease stabilization in about 50% of participants compared to less than 20% with placebo at Month 30, as measured by NT-proBNP levels. The drug demonstrated the fastest benefit observed in any Phase 3 ATTR-CM study to date, with results visible in just 3 months.
The data was presented at the European Society of Cardiology Congress 2025 in Madrid, highlighting acoramidis's potential as a transformative therapy for ATTR-CM patients.BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company focused on genetic diseases, has announced its participation in three major healthcare investor conferences in September 2025. The management team will host fireside chats at the Wells Fargo Healthcare Conference in Boston (September 3), the Cantor Global Healthcare Conference in New York (September 4), and the Morgan Stanley Global Healthcare Conference in New York (September 8).
Investors can access live webcasts of the presentations through BridgeBio's investor relations website, with replays available for 90 days following each event.
BridgeBio Pharma (Nasdaq: BBIO) announced its upcoming presentations at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The company will present additional open-label extension data from the ATTRibute-CM study through one oral presentation and two ePosters.
The presentations include data on cardiovascular mortality reduction at Month 42, NT-proBNP improvements at Month 30, and beneficial effects on NAC ATTR Stage changes. Key presenters include experts from Stanford University, UChicago Medicine, and University College London's Centre for Amyloidosis.
BridgeBio Pharma (Nasdaq: BBIO) reported strong Q2 2025 financial results, with total revenue of $110.6 million, including $71.5 million from Attruby® net product revenue. The company's flagship drug Attruby has gained significant traction with 3,751 unique patient prescriptions from 1,074 unique prescribers.
New analyses from the ATTRibute-CM study reinforced Attruby's clinical profile, showing a 59% relative risk reduction in variant ATTR-CM patients and a 31.6% relative risk reduction in mortality associated with increased TTR stabilization. The company ended Q2 with a strong cash position of $756.9 million.
BridgeBio expects multiple key Phase 3 trial results in fall 2025, including FORTIFY (BBP-418 for LGMD2I/R9) and CALIBRATE (encaleret for ADH1), with PROPEL 3 (infigratinib for achondroplasia) results expected in early 2026.
BridgeBio Pharma (Nasdaq: BBIO) has published a significant genetic analysis study in the American Journal of Human Genetics, examining over 100 unique variants associated with autosomal dominant hypocalcemia type 1 (ADH1). The research revealed that approximately 25,000 people in the US and EU carry ADH1-causing variants, with a frequency of ~3.7 per 100,000 individuals.
The study highlighted that only 20% of individuals with ADH1-linked genetic variants have been properly diagnosed, indicating a substantial gap in disease recognition. Additionally, researchers identified nine novel gain-of-function CASR variants. The company's Phase 3 CALIBRATE trial for encaleret, potentially the first approved therapy for ADH1, is fully enrolled with 71 participants, with topline results expected in H2 2025.
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company specializing in genetic diseases, has scheduled its second quarter 2025 financial results conference call for Tuesday, August 5, 2025, at 4:30 pm ET. The company will release its financial results and business updates after market close on the same day.
Investors and interested parties can access the live webcast through BridgeBio's investor relations website. A replay will be available for 30 days following the event.
BridgeBio Pharma (Nasdaq: BBIO) has secured a $300 million upfront payment through a partial monetization of European royalties for BEYONTTRA®, their ATTR-CM treatment. The deal involves selling 60% of royalties on the first $500 million of annual BEYONTTRA European sales to HealthCare Royalty and Blue Owl Capital, with payments capped at 1.45x.
The transaction builds upon BridgeBio's existing partnership with Bayer Consumer Care AG, from which they've already received $210 million in upfront and regulatory milestones, with an additional $75 million in near-term milestone payments expected. The Bayer agreement includes tiered royalties starting in the low-30% range on European net sales.
Clinical data from the ATTRibute-CM study showed significant efficacy, including a 42% reduction in composite ACM and recurrent CVH events at Month 30, and a 50% reduction in cumulative CVH events. The drug is now approved as Attruby in the U.S. and as BEYONTTRA in Europe, Japan, and the UK.
[ "Secured $300 million immediate non-dilutive capital through royalty monetization", "Already received $210 million in upfront and regulatory milestones from Bayer partnership", "Additional $75 million in near-term milestone payments expected", "Clinical trials showed 42% reduction in composite ACM and CVH events", "Achieved 50% reduction in cumulative CVH events in Phase 3 study", "Obtained regulatory approvals across major markets (US, Europe, Japan, UK)", "Structured deal preserves upside potential with 1.45x payment cap" ]BridgeBio Pharma (Nasdaq: BBIO) announced an upcoming investor webinar scheduled for July 11, 2025, at 8:00 am ET. The webinar will feature Dr. Matthew Wicklund, a distinguished Professor of Neurology from UT Health Science Center San Antonio, who will discuss limb-girdle muscular dystrophy (LGMD), with a focus on LGMD2I/R9.
The presentation will include insights from Dr. Wicklund, who has extensive experience with over 35 multi-center clinical trials and 200+ publications. Additionally, executive members will provide updates on the BBP-418 program and discuss anticipated Phase 3 interim analysis results expected in H2 2025. The webinar will be accessible through BridgeBio's investor website, with a replay available for 30 days.